Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Teladoc (TDOC) Stock Price

Headlines about Teladoc (NYSE:TDOC) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Teladoc earned a news impact score of 0.20 on Accern’s scale. Accern also gave media stories about the health services provider an impact score of 45.4480679687445 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news articles that may have impacted Accern’s analysis:

Several equities analysts recently issued reports on the company. Chardan Capital upped their target price on Teladoc from $30.00 to $41.00 and gave the company a “buy” rating in a research report on Tuesday, June 20th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $27.00 price target on shares of Teladoc in a report on Monday, June 19th. Canaccord Genuity reaffirmed a “buy” rating and issued a $42.00 price target (up from $34.00) on shares of Teladoc in a report on Tuesday, June 20th. William Blair reaffirmed an “outperform” rating on shares of Teladoc in a report on Tuesday, June 20th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $32.00 target price on shares of Teladoc in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $35.55.

Shares of Teladoc (NYSE:TDOC) opened at 29.50 on Friday. The firm’s market cap is $1.67 billion. Teladoc has a one year low of $14.00 and a one year high of $36.90. The stock’s 50 day moving average is $33.13 and its 200-day moving average is $27.90.

Teladoc (NYSE:TDOC) last announced its earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.02. The firm had revenue of $44.60 million during the quarter, compared to analysts’ expectations of $44.39 million. Teladoc had a negative net margin of 34.57% and a negative return on equity of 16.65%. Teladoc’s revenue for the quarter was up 68.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.38) earnings per share. Analysts anticipate that Teladoc will post ($1.44) EPS for the current fiscal year.

In other news, CEO Jason N. Gorevic sold 19,991 shares of the firm’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $32.89, for a total value of $657,503.99. Following the transaction, the chief executive officer now directly owns 831,650 shares in the company, valued at approximately $27,352,968.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Adam C. Vandervoort sold 53,806 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $30.92, for a total transaction of $1,663,681.52. Following the completion of the sale, the insider now directly owns 33,008 shares in the company, valued at approximately $1,020,607.36. The disclosure for this sale can be found here. Insiders have sold a total of 107,186 shares of company stock worth $3,352,950 over the last quarter. 5.94% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This report was posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/teladoc-tdoc-receiving-somewhat-positive-press-coverage-report-shows-updated-updated.html.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Insider Buying and Selling by Quarter for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply